Rani Therapeutics (NASDAQ:RANI) PT Lowered to $9.00 at HC Wainwright

Rani Therapeutics (NASDAQ:RANI) had its target price cut by HC Wainwright from $13.00 to $9.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also commented on RANI. Oppenheimer initiated coverage on shares of Rani Therapeutics in a research note on Friday, August 2nd. They set an outperform rating and a $17.00 price target on the stock. BTIG Research boosted their target price on Rani Therapeutics from $7.00 to $14.00 and gave the company a buy rating in a report on Thursday, May 9th. Rodman & Renshaw initiated coverage on Rani Therapeutics in a research report on Thursday, June 13th. They issued a buy rating and a $10.00 target price for the company. Finally, Maxim Group assumed coverage on Rani Therapeutics in a research report on Friday, June 14th. They set a buy rating and a $15.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $12.38.

Rani Therapeutics Trading Up 4.1 %

RANI opened at $2.79 on Friday. The company has a debt-to-equity ratio of 3.10, a quick ratio of 1.93 and a current ratio of 1.93. Rani Therapeutics has a one year low of $1.82 and a one year high of $8.75. The company has a market cap of $140.67 million, a P/E ratio of -2.16 and a beta of 0.15. The business’s 50-day simple moving average is $3.37 and its 200-day simple moving average is $4.15.

Rani Therapeutics (NASDAQ:RANI) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.03. As a group, equities research analysts expect that Rani Therapeutics will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Rani Therapeutics

A hedge fund recently bought a new stake in Rani Therapeutics stock. Marshall Wace LLP acquired a new stake in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,247 shares of the company’s stock, valued at approximately $81,000. 30.19% of the stock is owned by hedge funds and other institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.